Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

istory of use of these products."

Study Design

COR-I was a 56-week placebo-controlled, double-blind randomized trial enrolling patients whose body-mass index (BMI) was between 30-45 kg/m(2) for patients with uncomplicated obesity, or BMI 27-45 kg/m(2) with controlled hypertension or dyslipidemia, or both. 1742 patients were randomized to receive either Contrave32, Contrave16 (16mg naltrexone SR/360mg bupropion SR), or placebo in a 1:1:1 ratio. Thirty-four sites in the United States participated in the study.

About Contrave

Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity. The two components of this combination therapy act in a complementary manner in the central nervous system. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior. In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating. The U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

About the Contrave Clinical Development Program

All four trials in the COR Phase 3 program (COR-I, COR-II, COR-BMOD and COR-Diabetes) were randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in bo
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... -- (Booth #7309, North Hall) — Dicom Systems ... Interface WebBridge, at the 100th annual RSNA Meeting held ... Chicago, Illinois . Photo ... medical facilities of any size, WebBridge allows any native ... data (e.g. JPEG, TFF, PDF, TXT, etc.) to DCMSYS ...
(Date:11/28/2014)... Nov. 28, 2014 Alimera Sciences, Inc. ... company that specializes in the research, development and ... a Securities Purchase Agreement with Deerfield Management and ... Alimera will issue shares of preferred stock to ... $50.0 million upon the satisfaction of certain closing ...
(Date:11/28/2014)... Chinese magnesium alloy maker DongGuan Eontec Co., ... alloy bone fixation screw has received Chinese regulatory inspection ... instrument and that the company acknowledges receipt of the ... Science and Technology Daily journalists Wang Xiangming and ... founder, Professor Li Yangde , has been a ...
Breaking Medicine Technology:Dicom Systems Announces WebBridge Interface at RSNA 2014 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 4
(Date:11/28/2014)... 28, 2014 Novatus, a leading ... Release v5.1 which provides customers with greater reporting ... , “As we continue to evolve and ... more functionality and improved performance in response to ... for Novatus. “With the enhancements that we have ...
(Date:11/28/2014)... Gables, Florida (PRWEB) November 28, 2014 ... Thanksgiving, Turbana and Sendik’s will present Feeding America Eastern ... with Sendik’s Food Market to donate a portion of ... participated in Sendik’s promotion, “7 Days, 7 Ways to ... throughout fall, Fyffes pineapples were two for $4 and ...
(Date:11/28/2014)... New York (PRWEB) November 28, 2014 ... continuing to move forward in New Jersey’s Bergen ... in a consolidated litigation established there is quickly ... List updated on November 18th shows 1,293 lawsuits ... created for lawsuits that allege complications resulting from ...
(Date:11/28/2014)... 2014 Dr. Andrew Campbell, one of ... the expansion of Quintessa Aesthetic Center into a third ... at W307 N1497 Golf Road in Suite 200 and ... Campbell, the new Delafield location will offer a variety ... including: Botox, filler injectables , micro laser peels, ...
(Date:11/28/2014)... 28, 2014 Dr. Diane Walder, one of ... new treatment to her practice called Ultrashape that is designed ... three inches in just six weeks. Ultrashape has been praised ... superior in results when compared to other types of external ... treat it,” said Dr. Walder. , According to Dr. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... Loyola University Health System study includes some unexpected ... Contrary to expectations, patients who died from their ... than patients who survived., "Perhaps a better understanding ... for therapies that further improve outcomes in burn ...
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... children and adolescents. In the current issue of ... 173-79), Susanne Walitza and her colleagues point out that ... course of the disease. Compulsive washing, the most ... in up to 87% of all patients; other common ...
... The United States should pay close attention to how the ... worth using factors that go beyond clinical and cost effectiveness, ... Bioethics. In a commentary to appear in the April ... , the bioethicists detail and discuss a new, "value-based pricing" ...
... establishes a unique system to perform in vivo ... networks that regulate hepatocyte proliferation during chronic liver ... that stable knockdown of the candidate gene by ... of mouse hepatocytes and also increase the regenerative ...
Cached Medicine News:Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Surprising finding from smoke inhalation study 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
Lachrymal cannula, straight....
Solo-care is a multi-purpose solution for cleaning, rinsing, disinfection and storing soft contact lenses....
Medicine Products: